Good afternoon, and welcome to Amwell's First Quarter 2022 Conference Call. Today’s call is being recorded. All lines have been place on mute. [Operator Instructions] At this time, I would like to turn the conference over to Sue Dooley, Head Of Investor Relations. Please go ahead.

Hell, everyone, welcome to Amwell’s conference call to discuss our first fiscal quarter of 2022. This is Sue Dooley of Amwell, Investor Relations. Joining me today are Amwell's, Chairman and co-Chief Executive Officer, Dr. Ido Schoenberg; and Bob Shepardson, our Chief Financial Officer. Early today, we distributed a press release detailing our announcement. The release is posted on our website at investrs.amwell.com and it’s also available from normal new sources. This conference call is being website live on the Investor Relation page of our website where a reply will be archived. Before we begin our prepared remarks, I would like to take this opportunity to remain during the course of this call, will make forward looking statements regarding projected operating results. And anticipate as market opportunities. This forward looking information is subject to the risk and uncertainties described in analyst filings with the SEC and actual results or events, may different materially. Except as required by law, we undertake no obligation to update or revise this forward looking statement. On this call, we will refer to both GAAP and non-GAAP financial measurements. A reconciliation of GAAP to non-GAAP financial measures is provided in our posted earnings release. With that, I will now turn the call over to Ido for his prepared remarks on the quarter. Ido?

Thanks, Sue, and welcome everyone. Q1 was an important quarter for our company as we continue to make progress on the launch of Converge our integrated technology platform that empowers and complements leading health care organizations as their pursue business initiatives in a fragmented and rapidly changing digital care delivery landscape. We are proceeding according to our plan for this year and our teams are engaged and inspired by the benefits of clarity of purpose and well-defined role in a digital-first future. I'll start by reviewing some highlights of the quarter and the full year. Then I'll take a moment to discuss the market for our solution and the key benefits assigned to patients providers, payers and innovators. Bob will then review some key metrics, our financial results and our guidance. Then we'll open the discussion with your questions. First, we are making good progress on our development of Converge and the delivery of our industry-leading digital care delivery enablement platform which has been our vision from day one. With a substantial part of our platform ready for live moments, our R&D efforts are now focused on bringing Converge over the finish line with several remaining capabilities that are in high demand from customers and prospects. We continue to prioritize existing customer migrations, while sales conversations around Converge are proceeding according to our plan. We have moved past the rapid deployments of Amwell Now customers that are now beginning the most complex and innovative migrations. Work on deployments of some of our largest and most strategic customers, continue on pace and these are setting the standard for digital health care. It solves the challenges of today and is built for the future. These close working partnerships are exciting, and provide evidence of our expertise and role is the pure play…

Thank you, Ido. And thank all of you for joining the call this evening. As on our last call, I will highlight some of our key operating metrics, then take you through our first quarter 2022 financial results. Active providers on our platform, specifically providers who are employed by our customers is an important signpost of the value they derive from using our software. We continue to see healthy growth here and ended the first quarter with over 102,000 active providers. This represents 12% growth compared to the fourth quarter, marking the third consecutive quarter of double-digit growth in this metric. Active providers grew 27% compared to a year ago, demonstrating the continued acceptance of virtual visits as a standard of care, total visit growth remained strong at 1.8 million in the first quarter, representing 15% growth versus last quarter. Scheduled visits grew 23% in the quarter and comprised 75% of our total visit volume, a new high for Amwell. As Ido discussed we are making steady progress on Converge development and the migration of our customers to our new platform is proceeding well. In the first quarter, total visits on Converge a healthy 40% quarter-over-quarter and comprised 10% of total visits which is in line with our fourth quarter. Our plan for this year calls for continued healthy growth in visits on Converge. And now, I'll turn to our financial results. Total revenue was $64.2 million, reflecting growth of 12% versus the first quarter of 2021. The components of revenue are as follows; subscription revenue was $28.7 million, reflecting growth of 17% year-over-year. Compared to Q4, subscription revenue declined 5%. This decline reflects an expected level of churn that was not yet balanced by new platform subscriptions given the timing of our new platform release. This was in line…

Thank you, Bob. We are proud of our team and we are encouraged by the start to the year that Q1 represents. Our role in the digital care delivery landscape is clear. The opportunity in front of us is large and expanding and we believe we are just getting started. Before we move to Q&A I wanted to update you on one final topic. One we know has rising importance not only with investors but also in our world today Amwell's approach to ESG. At Amwell, our values have always been core to who we are and service the foundation on which we strive to build a sustainable growth business and promote the long-term interests of our stakeholders. We believe we have a meaningful ESG story to tell around our people, our products and our processes and we are eager to help the world see our company through an ESG lens. We plan to provide more information regarding our approach to ESG later this year in an inaugural report that aligns with leading reporting frameworks. We look forward to sharing it with you. Thank you for your time. Operator, please open the call up for Q&A.

[Operator Instructions] Your first question comes from the line of Ricky Goldwasser with Morgan Stanley. Your line is open.

Yes. Hi, thank you. This is Craig on for Ricky. I appreciate all the color that you provided on Converge. If I can just ask from an enterprise demand standpoint more broadly some companies have cautioned about lengthening sales cycles and uncertain macro just what you're seeing in the marketplace and how it may be the same or different for you just given you are in the midst of a product cycle and you're ramping with Converge now?

Craig, that's a great question. On the one hand, one cannot ignore the headwinds in the market at large. Challenges with the economy, fears of inflation, uncertainty and so on and so forth. On the flip side, our enabled platform is addressing, most of those challenges for our clients. So if it's a tradition burnout, if it's growing efficiency, if it's improved efficient access to care services that eventually improve financial and clinical outcomes, all those things are becoming more relevant in higher demand than ever. It is also true that enterprise platforms take longer to integrate and as a result, they have their own cycle of revenue recognition. On the fixed side, these are significantly larger deals with much greater upside. The net of it that we reiterate today our guidance for the year and we're not seeing any material changes to the dynamics that we put in our model that we shared with you a few months ago.

Got it. Appreciate that. Thank you.

Your next question comes from the line of Charles Rhyee with Cowen. Your line is open

Yes. Thanks, guys and thanks for taking the question. I wanted to ask you I guess two items really. One is the partnership with LG. Maybe you can give us some more details around what the – how that will work? I know you had a partnership several years ago with Samsung but that had ended. Just trying to understand, what's different time or how is it different? And how we should think about the economics there I'm guessing revenues show up in the innovator line? And then secondly, the MSK program you're partnering with SWORD Health here. Is this an example of sort of the app store concept that you have talked about in the past that will be enabled to Converge? And just ran a little bit on the economics here as well. Thanks.

Hi, Charles, thank you. Great questions. So we are really trying to create a seamless single healthcare experience that brings together all the different touch points. We believe that things like cell phones for example are going to be incredibly important as the trusted touch point for many patients and growing number of providers but one cannot ignore the television. The television is present in so many rooms, in the living room of patients. And as carriers moving home, our ability to create a robust seamless integrated experience is a very important last mile element. It's well known that LG is incredibly popular. So we could use their reach to interact with many more patients. And that really is the promise of this relationship. While this partnership really drives some licensing revenues from the get-go, main value relates to its strategic value of connecting another very important touch point to the singular experience. So we feel great about where we are. You mentioned earlier a partnership. The world has changed. World has changed in a decade. What's possible today on an Android infrastructure and the capabilities of Connected Television is mild apart what it was a decade ago. So much more is possible today and we feel great about this one element. Your second comment is also very on point in the sense that while of course musculoskeletal program is very, very valuable. One of the great things here is our ability to demonstrate how an entire program created by a third-party is embedded in the singular experience that I talked about earlier. While SWORD did not really go through the App Store experience formally, the process they went through integrating and creating a partnership with us is indeed demonstrative of our plan to include many more third parties and offer our customers and their patients and providers much more choice as they develop their own digital health strategy.

Your next question comes from the line of Cindy Motz with Goldman Sachs. Your line is open.

All right. Thanks. And thanks for taking my questions. So it sounds like people like Converge, the people who have converted. And I know you said it's about 10% of the visits. Can we assume like that's about -- I mean is that what percentage of clients is that? And then -- with COVID slowing, I mean maybe some of the distractions going away -- or I don't know COVID maybe have another wave, but do you think -- I mean is the cadence that you sort of suggested last quarter, I mean do you still see that happening? Maybe could it be a little better? And then you had said too that the path to profitability you're good with still right the longer term like around -- it wouldn't be point per year but like around 20% for the out years? Thanks.

Hi, Cindy, good to hear your voice. Does not really count like a single question, but let it go. So in essence when -- you're absolutely right that we are very encouraged by what we see in Converge. As I mentioned, the accounting number of accounts can be extremely confusing because at the getgo we had so many accounts coming in but their relative contribution to revenues and their level of sophistication in real value generation is very, very different for very larger payers. If you compare the small practice and Anthem, it's very difficult to compare and could be misleading. So while the Converge visit growth is not an exact science, it does give you some indication that basically we're going according to plan which is exactly the case. I'm happy to reiterate that not only our guidance for this year, but also a path to profitability plan is very much on check and represent a good mix of investment that we'd like to have with providing a path to cash flow positive for our stakeholders to reduce the risk in our company and increase value. Most importantly, the last part of your question really allows me to maybe focus a little bit more about the point that is often missed by some. And that is the fact that many people keep focusing on the number of visits that we provide or the impact of the pandemic on our future. I would like to suggest that what we are seeing is not a fashion or a quarterly trend, but something far greater than that. So we could have zoom out for a second and maybe realize that we are seeing a whole transformation health care system. Once that started more than a decade ago in 2010 with the adoption of the EHRs, really the start of the healthcare transformation. And the pandemic COVID added really a big contribution to the adoption of virtual care. Lots of people tried it for the first time and that was incredibly important in a way of growing adoption. What we're seeing right now is the added component of automation coming in. And the three components access to physical care more and more virtual services and automation that are connected to the main path of care are driving what we see. It didn't start yesterday and it's not going away tomorrow. If anything we got some acceleration but this is a trend that we have a very high degree of confidence in. It's incredibly complex but yes incredibly valuable. So I don't think there is a reason for us to second guess what we shared with you. It's not a path that happens overnight but it's a very clear path. I'm thrilled by the choices we've made creating Converge, it’s a giant cooling effort. But in my opinion it's going to pay off in dividends by creating something that the market really needs today because of the enormous value of integrated care delivery system.

Great. Thank you.

Your next question comes from the line of Stephen Baxter with Wells Fargo. Your line is open.

Yeah, hi. Thanks. Just a follow-up a little bit on one of the prior questions. We're hearing from the hospitals that their financials were under a lot of pressure even before the acceleration that we've seen in inflation. So, obviously, you do see yourself as helping address the cost problem over the longer term and I get to your existing customer migrations seem like they're well on track. But for new customers it would be interesting to hear a little bit more about why you don't think there will be impacts either from competing budget priorities or just the focus of these hospital management teams? Thank you.

Stephen a very good question although I have to admit I didn't say there is no impact. I said that the impact that we see could be balanced by other elements. There is clearly some serious struggling going on because of the economic headwinds. But we definitely see. It's important to realize that when we talk to our customers, the first thing they say is that they have -- they realize the enormous potential of digital solutions but they have so many of them, and there is enormous course not only in the direct cost of maintenance and the difficulties in integration, but also the impact on the provider experience, the training things of this nature. And where we are able to Real fix a lot of these pain points. We are not only adding efficiency but we are also touching the issues of team burn out. So when we talk to our client’s new ones that you asked us to focus on, they really want to narrow the number of platforms that they have and they expect the platform that they choose to do much more for many more people. There is also a growing realization, the data is incredibly important. In a world that focuses on value, you cannot really have one platform that aggregates information in-house or in-patient, another one that focuses on virtual visits. And then the third one that focuses on automated care and programs. You need to bring all this data in a patient-centric way together, and we offer that and of course that is an important element that could eventually contribute to the top line and to efficiency. So I would summarize by saying that the world has definitely got more complicated. Luckily for us, we anticipated that complexity and build an infrastructure that is just for the doctor ordered in many ways to really fight a lot of those challenges and headwinds. And we believe and we see that it's well understood by not only existing clients but also a new client and all of you are going to see some real-world example beyond what I mentioned pretty soon.

Your next question comes from the line of Jessica Tassan with Piper Sandler. Your line is open.

Hi. Thank you so much for taking the question. So I think my first -- my question would just be on the payer version of Converge. Where are we in the development of that product? And then, when do you anticipate sort of migrating your payer customers onto the operated version of Converge? And then just in terms of the hospital customers that you guys have announced so far this afternoon. Can you just help us understand which of those in animal customers? And then, which of those were new customers entirely signing on to the Converge platform for the first time. Thanks so much.

Hi, Jessica. Well, there is no payer version of Converge. There is one Converge. That's the beauty of it. It's really complex to create one Converge but you're absolutely right. That we save the best for last and the payer elements are coming last in our delivery cycle. I'm happy to share the news as we talked about also on the last quarter that in the second half, you're going to see go lives not only of employers and delivery networks and practices but also of payers. So, we are beginning to onboard the payers very soon. And that process is going to continue in Q2 into the next the next year. Some of those players are very large and require a long list of integration points. Yet, they are -- we are very encouraged by their determination and understanding about the new opportunities that the new upgrade will offer them. As far as the customers I mentioned, honestly, I can't swear but as far as I remember the few names that we mentioned on the call are all existing relationships of Amwell. Of course, we don't have only existing customers we have some new ones, but I wanted to focus on our very impressive list of achievements that we see from existing customers. I want just to make it very clear that there are many, many more names and use cases and stories that we didn't have time to mention on the call. One of the greatest benefits of creating a platform that once it's there you sort of sit back and become amazed by the value that is generated by the innovation of our customers and partners. So, maybe to end your question, I'll just give you one example -- one more example of a delivery network that you asked about maybe Spectrum Health. So they are VP of care management, which are there went public recently about the use of automated technology by Amwell that allow them to interact with patients following their visits to the emergency. And that single modality loan generated 5% reduction in ED and acute care utilization proving value of $998,000 in care savings for that organization. So interestingly Dr. Baird also said that they were able to use our technology to create a new transition team that really stands between patients and the ED to buffer the demand to manage their care, resulting in not only great patient experience but also such a powerful provider experience that she called it a great staff recruitment tool. So as you can tell, I can sit here for a really long time and tell you many more stories. But unfortunately, we don't have time today. Q – Jessica Tassan: Got it. Thank you. That’s helpful.

Your next question comes from the line of David Larsen with BTIG. Your line is open.

Hi. Total provider visits came in a little bit ahead of what we were modeling. Any sense for what drove that? And do you have an AMG provider visit count for the quarter? Thanks so much.

I'll take that. So the AMG visits on the quarter were I think I said they were flat with what we had in the fourth quarter 390,000 paid visits, okay? And what drove total visits higher, I think was just continued exceptional performance in terms of the growth of visits from our software customers, right? So I think I said we had our third consecutive quarter of double-digit growth there. And so we're very pleased to report that that continues. I shouldn't say it's a surprise to the upside but I think continues to indicate really strong user benefits, customer benefits from the platform.

Great. And then can you talk a little bit about hospital buying patterns? I think last quarter there was some commentary around hospitals being focused on COVID and the spike in the Delta variant. And there may have actually been some elongated buying decisions. What are you seeing this quarter? Are we now through that? Are hospitals rapidly more rapidly purchasing these? And do you have any color around bookings trend on a year-over-year basis or backlog trend on a year-over-year basis? Thanks.

So David, as you know, we don't really report on those metrics but I would say this what we see is growing interest on the most sophisticated part of our offering namely Converge, but pretty much everyone and especially large delivery networks. The mechanics, the dynamics of the sale per design is longer. You need to assess many more parts, you need to think about your strategy in your future. And once, the decision is being made, it's a larger decision with larger average contract value, typically, it takes a little longer to implement. So that should influence the micro dynamics, if you will of our revenue, which we talked about at nauseam, going forward. A general trend, we expect to see growing competition at the lower end of the market people, who just want to use a video dialer that see for a compliant. There are many players in this area. The competition is, fierce. And while we think greatly, about our platform our added value there is much, much smaller versus the added value in the large integrated delivery capabilities that I mentioned, earlier. So in the net of it, that we are really seeing a transformation of Amwell, from a service company with technology into a large enterprise delivery, also as it relates to the buying dynamics of our clients.

Your next question comes from the line of Ryan MacDonald with Needham. Your line is open. Q – Unidentified Analyst: Hi. Thank you for the question. This is Matt Shae [ph] on for Ryan. I wanted to touch on the dermatology and MSK program. Curious, if health plans will be able to roll out these programs when they adopt Converge or if it will be an upsell after the Converge implementation and as a follow-on, was this at all motivated to better position yourself to cater to the 12 telehealth specialties that allow Medicare Advantage plans to gain a 10% network adequacy credit, or was there some other motivation that drove the launch of these programs? Thanks.

So Matt, the answer is yes and yes. Although, we don't try to hit the agenda of the program always for a specific need but in the same way that Apple, doesn't necessarily select apps for one reason or another. What we want to do is, to create comprehensive diversity to allow as many options as possible, to make sure that our clients are as successful as they can. So dermatology in are just important topics, in the same way that the every health is the super important or chronic care. You should definitely expect, to see us covering bigger and bigger part of the carrier continuum in all those in integration, into in-network physical options into virtual growing number of virtual options, and a growing number of automated options. A substantial part of what we offer today, is made by Amwell but in the future as I mentioned before, we definitely expect to have lots of other third-parties contribute their own, even if they sometimes overlap or compete with our own house offering, if you will.

Your next question comes from the line of Eric Percher with Nephron Research. Your line is open.

Thank you. Question relative to model cadence this year, and it's one part revenue one part expense. On the subscription revenue side I heard you loud and clear in terms of the expectation for a quarterly step down and the issue here being the new platform not ready to kind of put up what's natural churn. What are your thoughts on how that progresses over the course of the year? And when you get to the point, where you see sequential growth in subscription? And then on expense, a similar question on R&D and your expectation for continued expansion and at what point we start to see R&D contract?

I would say, I have the same answer to both questions Eric second half and where exactly in the second half. I don't want to get too specific. But we expect that, we'll start to recognize revenue from some go-lives – large go-lives in the second half. So I would expect that revenue growth on the subscription side resumes then. I think some of what we'll see in the second quarter is very similar to kind of, what we had in the first quarter just given the setup. It's a very similar setup, although, yeah it's a similar setup. And on the expense side R&D specifically, I would expect that to continue to climb next quarter and then flatten and certainly decline by the fourth quarter. So no change there in terms of how we characterize that last quarter more kind of growing and plateauing in the first half and then plateauing to shrinking in the second half.

Your last question comes from the line of Allen Lutz with Bank of America. Your line is open.

Hey, Ido and Bob. Thanks for taking the question. Active providers were up nicely again this quarter. I guess, is that coming from legacy customers adding new providers, or is it coming from new customers? And if it's coming from legacy customers, where exactly is that growth coming from? And then on MSK and derm, can you just talk about how that's going to hit the P&L? Is any of that going to flow through the visits line? Thanks.

I'll let Bob answer more specifically the -- although I'll give it to try to answer both questions. So yes it is -- the growth is mostly coming from our legacy -- our existing clients. As I mentioned earlier our platform can things that clients are discovered covering the different options. And as a result more and more providers are involved. A lot of these visits are specialty visits a lot of these visits are part of sophisticated programs. It is very clear ROI really across the entire care continuing. As you know this is so important to us. We believe that getting providers to trust our platform in our ability to retain them in growing the opportunity for patients to see their own doctor was always really the number one KPI in Amwell and we are so glad to see this growing so well. In general program like MSK are reoccurring revenues not unlike SaaS revenue. They do have an element typically over clinical visits. So it's a combo of some, kind of, a PM P&C and clinical fees is a general rule. Of course there could be other programs that are exclusively PMT and I am hard-pressed to think about the program that is exclusively visit. That's less say likely.

I don't have anything to add really to I don't think it's definitely the our customers are the legacy customers that are adding these. And I would say it kind of goes hand-in-hand with what's going on from a scheduled visit perspective as well. I mentioned that scheduled visits were 75% of our total visit volume which was a new high for us. So I think it's just when you see the number of providers active providers growing on the network and the composition of visits shifting to scheduled visits meaningfully over the course of the last year it just kind of speaks to how this is very natural growth normal growth and that this is not driven by any COVID-type dynamics or anything like that. This is the evolution of the offering.

That is all the time we have for questions. I'd like to turn the call back to Dr. Schoenberg for closing remarks.

Well, thank you so much everyone. I'm very pleased to see the growing level of understanding of Amwell and Converge in how we differ from some other business activities in the market. What we do is exciting and has an enormous upside. And we really appreciate the time to really understand our mission and where we're going. We look forward to seeing you again soon.

This concludes today's conference call. Thank you for joining. You may now disconnect.